Trails Edge Capital Partners LP Makes New $8.45 Million Investment in CAMP4 Therapeutics Corporation $CAMP

Trails Edge Capital Partners LP acquired a new position in shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,932,937 shares of the Wireless communications provider’s stock, valued at approximately $8,446,935. CAMP4 Therapeutics accounts for approximately 0.0% of Trails Edge Capital Partners LP’s portfolio, making the stock its 27th biggest holding. Trails Edge Capital Partners LP owned 3.08% of CAMP4 Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $86,000. Bridgeway Capital Management LLC purchased a new stake in shares of CAMP4 Therapeutics during the second quarter worth $36,000. Two Sigma Investments LP purchased a new stake in shares of CAMP4 Therapeutics in the 3rd quarter valued at $292,000. Vivo Capital LLC purchased a new position in shares of CAMP4 Therapeutics during the 3rd quarter worth approximately $11,765,000. Finally, Jefferies Financial Group Inc. purchased a new position in shares of CAMP4 Therapeutics during the fourth quarter valued at approximately $70,000.

CAMP4 Therapeutics Stock Performance

Shares of CAMP traded up $0.01 during mid-day trading on Friday, hitting $4.15. 142,054 shares of the company traded hands, compared to its average volume of 187,615. The stock has a 50-day moving average price of $4.13 and a two-hundred day moving average price of $4.36. CAMP4 Therapeutics Corporation has a 1 year low of $1.41 and a 1 year high of $7.75. The stock has a market cap of $260.41 million, a price-to-earnings ratio of -1.79 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The firm had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. On average, analysts forecast that CAMP4 Therapeutics Corporation will post -0.57 EPS for the current year.

Insider Buying and Selling at CAMP4 Therapeutics

In related news, Director Richard A. Young bought 16,378 shares of the stock in a transaction dated Monday, August 3rd. The stock was bought at an average cost of $1.65 per share, with a total value of $27,023.70. Following the completion of the acquisition, the director owned 186,388 shares of the company’s stock, valued at $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Andrew J. Schwab sold 114,700 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $4.54, for a total value of $520,738.00. Following the completion of the transaction, the director directly owned 2,465,298 shares in the company, valued at approximately $11,192,452.92. The trade was a 4.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders bought 36,031 shares of company stock valued at $59,451 and sold 193,613 shares valued at $888,037. 21.69% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 10th. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Weiss Ratings upgraded shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Finally, Zacks Research upgraded CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, CAMP4 Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $9.56.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.